Taysha Gene Therapies, Inc. $TSHA Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC cut its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 93.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 32,949 shares of the company’s stock after selling 460,352 shares during the period. SG Americas Securities LLC’s holdings in Taysha Gene Therapies were worth $108,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Jefferies Financial Group Inc. grew its position in shares of Taysha Gene Therapies by 4,105.3% in the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after purchasing an additional 10,068,479 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in Taysha Gene Therapies in the 2nd quarter worth about $11,178,000. MPM Bioimpact LLC purchased a new stake in Taysha Gene Therapies in the 2nd quarter valued at about $6,823,000. Octagon Capital Advisors LP increased its stake in shares of Taysha Gene Therapies by 17.7% during the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock valued at $29,089,000 after acquiring an additional 1,892,500 shares during the last quarter. Finally, Stempoint Capital LP purchased a new position in shares of Taysha Gene Therapies during the 2nd quarter worth about $2,781,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Down 1.3%

Shares of Taysha Gene Therapies stock opened at $4.51 on Friday. Taysha Gene Therapies, Inc. has a twelve month low of $1.05 and a twelve month high of $6.02. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -13.67 and a beta of 1.02. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. The company has a fifty day moving average price of $5.12 and a 200 day moving average price of $4.11.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on TSHA shares. Wall Street Zen downgraded shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. JMP Securities set a $8.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Chardan Capital restated a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.67.

Insiders Place Their Bets

In related news, CFO Kamran Alam sold 78,968 shares of the firm’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $375,098.00. Following the completion of the sale, the chief financial officer directly owned 1,467,635 shares of the company’s stock, valued at approximately $6,971,266.25. This trade represents a 5.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock in a transaction on Monday, December 1st. The stock was sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the sale, the insider directly owned 1,006,439 shares in the company, valued at $4,539,039.89. This trade represents a 20.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 967,140 shares of company stock worth $4,510,613 in the last 90 days. 3.78% of the stock is owned by company insiders.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.